MedTrace Logo

DECT Study in Allopurinol-Treated Gout Patients

NCT02393560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2017-01-25

No results posted yet for this study

Summary

The purpose of this study is to determine presence and volume of monosodium urate (MSU) crystal deposits as determined by dual-energy computed tomography (DECT) imaging in gout subjects treated with allopurinol with and without visible tophi.

Conditions

Interventions

PROCEDURE

DECT scan

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Nihar Bhakta, MD · Ardea Biosciences, Inc.

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-07-31
Completion
2016-10-31

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393560 on ClinicalTrials.gov